Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8752596 | 0.80 | CES2 (0.52) | TSHRTDP1ALDH1A1HSD17B10ATM | |
| SCHEMBL19464085 | 0.78 | TDP1 (0.48) | TSHRTDP1ALDH1A1HSD17B10AAK1 | |
| SCHEMBL3875454 | 0.77 | TDP1 (0.58) | TSHRTDP1ALDH1A1HSD17B10AAK1 | |
| SCHEMBL17552375 | 0.76 | TSHR (0.46) | TSHRTDP1ALDH1A1HSD17B10AAK1 | |
| Hydrochloric Acid SCHEMBL31332428 | 0.76 | TDP1 (0.57) | TSHRTDP1ALDH1A1HSD17B10AAK1 | |
| SCHEMBL10442833 | 0.76 | TDP1 (0.55) | TSHRTDP1ALDH1A1HSD17B10AAK1 | |
| SCHEMBL10770600 | 0.76 | CES2 (0.50) | TSHRTDP1ALDH1A1HSD17B10AAK1 | |
| Hydrogen Peroxide SCHEMBL28425777 | 0.75 | TDP1 (0.64) | TSHRTDP1ALDH1A1HSD17B10F2 | |
| SCHEMBL260960 | 0.75 | TDP1 (0.64) | TSHRTDP1ALDH1A1HSD17B10F2 | |
| SCHEMBL29199324 | 0.75 | TDP1 (0.64) | TSHRTDP1ALDH1A1HSD17B10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| CN-102630227-B | Be used for the treatment of the bisphosphonate compound of bone metabolism disturbance | WARNER CHILCOTT Co.,LLC (US) | 2016-03-23 | — | — | CN | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2493905-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | Warner Chilcott Company, LLC (PR) | 2012-09-05 | — | — | EP | disclosed |
| CN-102630227-A | Bisphosphonate compounds for treating bone metabolism disorders | WARNER CHILCOTT CO LLC | 2012-08-08 | — | — | CN | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | TSHR 3291/4885TDP1 4616/4885ALDH1A1 2404/4885 |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | TSHR 3291/4885TDP1 4616/4885ALDH1A1 2404/4885 |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | TSHR 3291/4885TDP1 4616/4885ALDH1A1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.